Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60‐year‐old Caucasian woman with ovarian carcinoma
- 18 November 2015
- journal article
- case report
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 81 (2) , 313-315
Abstract
Aim: The aim of the present case report was to describe a novel pharmacokinetic drug–drug interaction between the antiplatelet agent clopidogrel and the antineoplastic agent paclitaxel.Methods: The patient was identified in a previously described cohort of 93 patients with ovarian carcinoma treated with paclitaxel. The effect of clopidogrel acyl‐β‐D‐glucuronide on the metabolism of paclitaxel was assessed in human liver microsomes. The analysis of clopidogrel in plasma and the quantification of paclitaxel and 6α‐hydroxypaclitaxel in in vitro samples were performed by liquid chromatography tandem mass spectrometry.Results: The patient was a 60‐year‐old female treated with an unknown dose of clopidogrel at the time of paclitaxel therapy. Clopidogrel was present in all three of the plasma samples obtained during paclitaxel dosing. Estimated unbound paclitaxel clearance was 238 l h−1, which was only 62% of the cohort geometric mean (385 l h−1; range 176–726). She was hospitalized three times, developed severe neuropathy and paclitaxel treatment was subsequently discontinued. In vitro, 30‐min preincubation with 100 μM clopidogrel acyl‐β‐D‐glucuronide inhibited the depletion rate of 0.5 μM paclitaxel by 51% and the formation rate of 6α‐hydroxypaclitaxel by 77%.Conclusion: This is the first report of a clopidogrel–paclitaxel interaction, suggesting that clinically used doses of clopidogrel can reduce the cytochrome P450 2C8 (CYP2C8)‐mediated systemic clearance of paclitaxel, leading to an increased risk of paclitaxel toxicity. Caution should be exercised whenever the simultaneous use of paclitaxel and clopidogrel cannot be avoided.Keywords
This publication has 7 references indexed in Scilit:
- CYP2C19*17increases clopidogrel‐mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrelClinical and Experimental Pharmacology and Physiology, 2014
- Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug InteractionsClinical Pharmacology & Therapeutics, 2014
- Impact ofABCB1Variants on Neutrophil Depression: A Pharmacogenomic Study of Paclitaxel in 92 Women with Ovarian CancerBasic & Clinical Pharmacology & Toxicology, 2011
- Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancerThe Pharmacogenomics Journal, 2010
- Association of Paclitaxel Pharmacokinetics with the Development of Peripheral Neuropathy in Patients with Advanced CancerClinical Cancer Research, 2005
- Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8.1994
- Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme.1994